Skip to main content
Top
Published in: Annals of Nuclear Medicine 10/2018

01-12-2018 | Original Article

The value of different 18F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients

Authors: Hoda Anwar, Thomas J. Vogl, Mahasen A. Abougabal, Frank Grünwald, Peter Kleine, Sherif Elrefaie, Nour-Eldin A. Nour-Eldin

Published in: Annals of Nuclear Medicine | Issue 10/2018

Login to get access

Abstract

Objective

Administration of postoperative chemotherapy to patients with completely resected stage I NSCLC is still a matter of debate. The aim of the present study was to evaluate the value of different baseline 18F-FDG PET parameters in identifying surgical stage I NSCLC patients who are at high risk of recurrence, and thus are indicated for further postoperative treatment.

Methods

This is a retrospective study, which included 49 patients (28 males, 21 females) with the median age of 69 years (range 28–84), who had pathologically proven stage I NSCLC. All patients underwent 18F-FDG PET/CT at baseline followed by complete surgical resection of the tumor (R0). Baseline SUVmax, MTV and TLG were measured. Patients’ follow-up records were retrospectively reviewed, and DFS (disease-free survival) was assessed. For each parameter, the most accurate cut-off value for the prediction of recurrence was calculated using the ROC curve analysis and the Youden index. DFS was evaluated for patients above and below the calculated cut-off value using the Kaplan–Meier method and the difference in survival between the two groups was estimated using the log-rank test.

Results

Median observation time of the patients after surgery was 28.7 months (range 3.5–58.8 months). 9 patients developed recurrence. The calculated cut-off values for SUVmax, MTV and TLG were 6, 6.6 and 33.6, respectively. Using these cut-offs, the observed sensitivity for SUVmax, MTV and TLG for prediction of recurrence was 100%, 89% and 89%, respectively, while the observed specificity was 43%, 73% and 65%, respectively. The difference in survival between patients below and above the cut-off value was statistically significant in all three studied parameters. The highest AUC was observed for MTV (AUC = 0.825, p = 0.003), followed by TLG (AUC = 0.789, p = 0.007), and lastly SUVmax (AUC = 0.719, p = 0.041). ROC curve analysis showed that volumetric parameters had better predictive performance than SUVmax as regards recurrence.

Conclusion

PET-derived parameters at baseline were predictive of recurrence in stage I surgical NSCLC patients. Moreover, the metabolic volume of the tumor was the most significant parameter for this purpose among the studied indices.
Literature
1.
go back to reference Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.CrossRef Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.CrossRef
2.
go back to reference Detterbeck F. Stage classification and prediction of prognosis: difference between accountants and speculators. J Thorac Oncol. 2013;8(7):820–2.CrossRef Detterbeck F. Stage classification and prediction of prognosis: difference between accountants and speculators. J Thorac Oncol. 2013;8(7):820–2.CrossRef
3.
go back to reference Chansky K, Sculier J-P, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.CrossRef Chansky K, Sculier J-P, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.CrossRef
4.
go back to reference Goodgame B, Viswanathan A, Zoole J, et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol. 2009;4(11):1370–4.CrossRef Goodgame B, Viswanathan A, Zoole J, et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol. 2009;4(11):1370–4.CrossRef
5.
go back to reference Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. Patnaik S, ed. PLoS One. 2016;11(1):e0146195.CrossRef Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. Patnaik S, ed. PLoS One. 2016;11(1):e0146195.CrossRef
6.
go back to reference Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364–70.CrossRef Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364–70.CrossRef
7.
go back to reference Kim D-H, Son SH, Kim C-Y, et al. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. Ann Surg Oncol. 2014;21(2):589–96.CrossRef Kim D-H, Son SH, Kim C-Y, et al. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. Ann Surg Oncol. 2014;21(2):589–96.CrossRef
8.
go back to reference Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer. 2006;119(4):955–60.CrossRef Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer. 2006;119(4):955–60.CrossRef
9.
go back to reference Peng S, Li X, Wang Y, Liu J. Effect of adjuvant chemotherapy on DFS for patients with stage I NSCLC. Zhongguo Fei Ai Za Zhi. 2017;20(7):485–9.PubMed Peng S, Li X, Wang Y, Liu J. Effect of adjuvant chemotherapy on DFS for patients with stage I NSCLC. Zhongguo Fei Ai Za Zhi. 2017;20(7):485–9.PubMed
10.
go back to reference Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71.CrossRef Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71.CrossRef
11.
go back to reference Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32(4):623–48 (discussion 649–50).PubMed Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32(4):623–48 (discussion 649–50).PubMed
12.
go back to reference Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The Visual Response Score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159–71.CrossRef Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The Visual Response Score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159–71.CrossRef
13.
go back to reference Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRef Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRef
14.
go back to reference Vincet T. DeVita Jr, Theodore S, Lawrence SAR. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015. Vincet T. DeVita Jr, Theodore S, Lawrence SAR. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015.
15.
go back to reference Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Fut Oncol. 2015;11(7):1083–91.CrossRef Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Fut Oncol. 2015;11(7):1083–91.CrossRef
17.
go back to reference Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. American College of Chest Physicians. Treatment of non-small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest. 2007;132(3 Suppl):234S–42S.CrossRef Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. American College of Chest Physicians. Treatment of non-small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest. 2007;132(3 Suppl):234S–42S.CrossRef
18.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRef
19.
20.
go back to reference Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg. 2008;34(4):892–7.CrossRef Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg. 2008;34(4):892–7.CrossRef
21.
go back to reference Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009;4(12):1473–9.CrossRef Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009;4(12):1473–9.CrossRef
22.
go back to reference Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part. J Thorac Oncol. 2010;5(5):612–9.CrossRef Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part. J Thorac Oncol. 2010;5(5):612–9.CrossRef
23.
go back to reference Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9(6):834–42.CrossRef Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9(6):834–42.CrossRef
24.
go back to reference Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;13(11):3255–63.CrossRef Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;13(11):3255–63.CrossRef
25.
go back to reference Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong C-YO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691–8.CrossRef Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong C-YO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691–8.CrossRef
26.
go back to reference Lin Y, Lin W-Y, Kao C-H, Yen K-Y, Chen S-W, Yeh J-J. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res. 2012;32(11):5087–91.PubMed Lin Y, Lin W-Y, Kao C-H, Yen K-Y, Chen S-W, Yeh J-J. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res. 2012;32(11):5087–91.PubMed
27.
go back to reference Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20(1):32–40.CrossRef Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20(1):32–40.CrossRef
28.
go back to reference Kim K, Kim S-J, Kim I-J, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33(6):613–20.CrossRef Kim K, Kim S-J, Kim I-J, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33(6):613–20.CrossRef
29.
go back to reference Melloni G, Gajate AMS, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013;39(11):1254–61.CrossRef Melloni G, Gajate AMS, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013;39(11):1254–61.CrossRef
30.
go back to reference Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56(1):45–9.CrossRef Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56(1):45–9.CrossRef
31.
go back to reference Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290–301.CrossRef Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290–301.CrossRef
32.
go back to reference Kao C-H, Lin S-C, Hsieh T-C, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39(8):1297–305.CrossRef Kao C-H, Lin S-C, Hsieh T-C, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39(8):1297–305.CrossRef
33.
go back to reference Fencl P, Belohlavek O, Harustiak T, Zemanova M. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012;33(11):1188–94.CrossRef Fencl P, Belohlavek O, Harustiak T, Zemanova M. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012;33(11):1188–94.CrossRef
34.
go back to reference Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–54.CrossRef Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–54.CrossRef
35.
go back to reference Kitao T, Hirata K, Shima K, et al. Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer. BMC Cancer. 2016;16(1):576.CrossRef Kitao T, Hirata K, Shima K, et al. Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer. BMC Cancer. 2016;16(1):576.CrossRef
Metadata
Title
The value of different 18F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients
Authors
Hoda Anwar
Thomas J. Vogl
Mahasen A. Abougabal
Frank Grünwald
Peter Kleine
Sherif Elrefaie
Nour-Eldin A. Nour-Eldin
Publication date
01-12-2018
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 10/2018
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1301-9

Other articles of this Issue 10/2018

Annals of Nuclear Medicine 10/2018 Go to the issue